Evidence map›Paper›PMID 40293707›Full record

ArticleMolecular neurobiology2025

L-DOPA Induces Spatially Discrete Changes in Gene Expression in the Forebrain of Mice with a Progressive Loss of Dopaminergic Neurons.

Anna Radlicka-Borysewska, Magdalena Ziemiańska, Mateusz Zięba, Łukasz Szumiec, Monika Bagińska, Magdalena Chrószcz, Sławomir Gołda, Jacek Hajto, Michał Korostyński, Grzegorz Kreiner and 3 more

Abstract read
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anna Radlicka-BorysewskaDepartment of Molecular Neuropharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland.ORCID http://orcid.org/0000-0002-4248-7182
Magdalena ZiemiańskaDepartment of Molecular Neuropharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland.ORCID http://orcid.org/0000-0001-6386-2343
Mateusz ZiębaLaboratory of Pharmacogenomics, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland.ORCID http://orcid.org/0000-0001-9917-303X
Łukasz SzumiecDepartment of Molecular Neuropharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland.ORCID http://orcid.org/0000-0001-8962-1273
Monika BagińskaDepartment of Brain Biochemistry, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland.ORCID http://orcid.org/0000-0003-2550-0645
Magdalena ChrószczDepartment of Molecular Neuropharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland.ORCID http://orcid.org/0000-0002-3157-458X
Sławomir GołdaDepartment of Molecular Neuropharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland.ORCID http://orcid.org/0000-0003-1663-0587
Jacek HajtoLaboratory of Pharmacogenomics, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland.ORCID http://orcid.org/0000-0002-7103-4246
Michał KorostyńskiLaboratory of Pharmacogenomics, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland.ORCID http://orcid.org/0000-0002-4273-7401
Grzegorz KreinerDepartment of Brain Biochemistry, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland.ORCID http://orcid.org/0000-0003-3719-2889
Joanna PeraDepartment of Neurology, Jagiellonian University Medical College, Krakow, Poland.ORCID http://orcid.org/0000-0001-6142-2969
Marcin PiechotaLaboratory of Pharmacogenomics, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland.ORCID http://orcid.org/0000-0003-2468-151X
Jan Rodriguez ParkitnaDepartment of Molecular Neuropharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland. janrod@if-pan.krakow.pl.ORCID http://orcid.org/0000-0003-0367-2331

Funding

Narodowe Centrum Nauki PRELUDIUM 2020/37/N/NZ4/03672
6 · The paper itself

Abstract

L-3,4-Dihydroxyphenylalanine (L-DOPA) is effective at alleviating motor impairments in Parkinson's disease (PD) patients but has mixed effects on nonmotor symptoms and causes adverse effects after prolonged treatment. Here, we analyzed the spatial profile of L-DOPA-induced gene expression in the forebrain of mice with an inducible progressive loss of dopaminergic neurons (the TIF-IA

Indexed as

Dopaminergic NeuronsGene Expression RegulationLevodopaProsencephalonAnimalsMaleMiceMice, Inbred C57BLTranscriptomeLevodopaForebrainL-DOPAMouse modelParkinson’s diseaseSpatial transcriptomics

Identifiers

PMID40293707
PMCPMC12367957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.